Scleroderma Diagnostics and Therapeutics Market Scleroderma Diagnostics and Therapeutics Market - | Page 2

These factors would help the market players to take strategic decisions in order to strengthen their positions and expand their share in the global market .
Global Scleroderma Diagnostics and Therapeutics Market : Segmentation
Based on indication , the global scleroderma diagnostics and therapeutics market has been segmented into localized and systemic scleroderma . Localized scleroderma affects only the skin , and in certain patients , the underlying muscle , however , systemic scleroderma ( also known as systemic sclerosis ) is much severe and affects the internal organs as well .
The major drug classes for treatment of scleroderma include Corticosteroids , Immunosuppressive Agents , Endothelin Receptor Agonists , Calcium Channel Blockers , PDE-5 Inhibitors , Chelating Agents , Prostacyclin Analogues , and Others . The others segment includes the drug classes of analgesics , proton pump inhibitors , prokinetic agents , H2 blockers and ACE inhibitors etc . which are used in symptomatic relief to the patient . Immunosuppressive agents and low dose corticosteroids are the most commonly prescribed agents to treat scleroderma .
Based on test type , the diagnostics market has been segmented into skin biopsy , imaging techniques , blood test , electrocardiogram and echocardiogram , and pulmonary function tests . Diagnosis of the disease is based on physician ’ s assessment of patients ’ medical history and clinical manifestations . In addition , tests and procedures are undertaken to validate the clinical diagnosis and exclude alternative diagnoses , and later for assessment of organ involvement and monitoring of disease progression .
Global Scleroderma Diagnostics and Therapeutics Market : Geographical and Competitive Dynamics
Geographically , the global scleroderma diagnostics and therapeutics market has been segmented into five regions : North America , Europe , Asia Pacific , Latin America , and Middle East & Africa . In addition , the regions have been further segmented by major countries for the scleroderma therapeutics market These include the U . S ., Canada , the U . K ., Germany , France , China , Japan , India , Brazil , Mexico , the UAE , and South Africa . The competition matrix section included in the report is likely to assist the existing players to increase their market shares and new companies to establish their presence in the radiodermatitis market .
The report also profiles major players in the scleroderma therapeutics and diagnostics market based on various attributes such as company overview , financial overview , SWOT analysis , key business strategies , product portfolio , and recent developments . Key companies profiled in the report include Actelion Pharmaceuticals , Inc ., Boehringer Ingelheim , Bayer AG , Cytori Therapeutics , Inc ., Cumberland Pharmaceuticals Inc , Gilead Sciences , Inc ., Pfizer , Inc ., and Sanofi .
Global Scleroderma Diagnostics and Therapeutics Market : Scope of the Report
This report on the global scleroderma diagnostics and therapeutics market analyzes the current and future prospects of the market . The markets of diagnostics and therapeutics are independently analyzed as two separate markets within the report . The market for scleroderma therapeutics is segmented based on drug class , indication and region , while the market for scleroderma diagnostics is segmented on the basis of test type and region . The report comprises an elaborate executive summary , including a market snapshot that provides overall information of various segments and subsegments . The research is a combination of primary and secondary research .